Lactoferrin and ferrous fumarate

Small molecule

Lactoferrin and ferrous fumarate is one of 35 small molecule programs targeting Iron deficiency anemia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Iron Deficiency AnemiaActive, not recruiting

Iron Deficiency AnemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

85 competitors in Iron Deficiency Anemia

#DrugCompanyPhaseTrials

Injectafer

AAmerican Regent, Inc.

Approved

13 2

Feraheme

AAzurity Pharmaceuticals

Approved

9 3

Folvite

Niacor

Cecon

MMcGuff Pharmaceuticals, Inc.

Approved

—6

Venofer

AAmerican Regent, Inc.

Phase 3

7 7

Dexferrum

NNew River Pharmaceuticals

Phase 3

2 8

Auryxia

KKeryx Biopharmaceuticals

Phase 3

1 9

Iron

WWatson Pharmaceuticals

Phase 3

5 10

IV Iron

Pfizer

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Iron deficiency anemia1 trial

Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy

Unknown status·—·Phase 1/2·NCT03484845·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lactoferrin and ferrous fumarate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactoferrin and ferrous fumarate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactoferrin and ferrous fumarate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assiut University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAssiut University

Lactoferrin and ferrous fumarate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Iron deficiency anemia1 trial

References

Drug Info

Quick Facts

Related News